Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Inc (DOW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Dow Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dow Inc trades at $30.63 (market cap $22.58B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dow Inc is far larger — about 287.5× Inovio Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.48% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

DOWINO
Market Cap
$22.58B$78.55M
Sector
Basic MaterialsHealth
52-Week High
$41.87$2.87
52-Week Low
$20.65$0.66
Enterprise Value
$38.27B$49.56M
Dividend Yield
4.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Inc

DOW trades at $30.64, up 0.2% with a bullish technical signal and recent earnings beats. The company shows declining revenue trends from $56.9B in 2022 to $40.0B in 2025, with negative net income margins. Analyst consensus is mixed with 33% buy ratings and a $35.11 price target, representing 15% upside. Recent dividend payment of $0.35 provides income support amid challenging fundamentals.

While technical indicators suggest near-term strength, fundamental challenges persist with negative profitability and declining cash flow. The stock offers potential upside to analyst targets but faces execution risks in a competitive chemical sector. Dividend yield provides some cushion, but investors need sustained operational improvement for meaningful long-term returns.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Inc

Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.

Read more on DOW

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO